MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
01 September 2022 - 8:00PM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of innovative
therapeutic products for patients with endocrine and orphan lung
diseases, announced today that its Chief Executive Officer, Michael
Castagna, PharmD, will participate in a Fireside Chat at the
H.C. Wainwright 24th Annual Global Investment Conference on
Tuesday, September 13, 2022 at 12:00 PM ET at the Lotte New York
Palace Hotel.
Interested parties can access a link to the on demand webcast of
the presentation from the Events & Presentations section of the
Company’s website at
https://investors.mannkindcorp.com/events-and-presentations.
The webcast replay may be accessed at the same location for 14
days.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the
development and commercialization of innovative therapeutic
products and devices to address serious unmet medical needs for
those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and
device engineering prowess to lessen the burden of diseases such as
diabetes, pulmonary arterial hypertension (PAH) and nontuberculous
mycobacterial (NTM) lung disease. Our signature technologies –
dry-powder formulations and inhalation devices – offer rapid and
convenient delivery of medicines to the deep lung where they can
exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide,
we are on a mission to give people control of their health and the
freedom to live life.
Please visit mannkindcorp.com to learn more, and
follow us
on LinkedIn, Facebook, Twitter or Instagram.
Contact: Rose
Alinaya, Investor Relations(818) 661-5000Email:
ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jun 2024 to Jul 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jul 2023 to Jul 2024